|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
CO-ADMINISTRATION MAY CAUSE INCREASE IN BLOOD PRESSURE
|
HALOTHANE DIMINISHES THE EFFECT OF ERGOTAMINE ON UTERUS
|
SYNERGISTIC ACTION BUT THERE IS INCREASED RISK OF UTERINE RUPTURE
|
SAQUINAVIR COMPETES FOR CYP3A ENZYME RESULTING IN IHBITION OF METABOLISM OF OTHER DRUG & CREATE THE POTENTIAL FOR SERIOUS / LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS OR PROLONGED SEDATION
|
BETABLOCKERS ENHANCE THE VASOCONSTRICTOR EFFECTS OF THE DRUG
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
METHYSERGIDE VASOCONSTRICTIVE EFFECTS ARE ENHANCED BY THE DRUG WHICH MAY LEAD TO ARTERIAL OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
SUMATRIPTAN & OTHER SEROTONIN AGONIST SHOULD BE GIVEN 24 HRS AFTER STOPPING ERGOTAMINE OR ERGOTAMINE SHOULD BE STARTED 6 HRS AFTER STOPPING SUMATRIPTAN OTHERWISE CHANCES OF PROLONGED VASOSPASTIC REACTIONS ARE HIGH
|
INCREASED PERIPHERAL VASOCONSTRICTION
|
CO-ADMINISTRATION MAY ENHANCE OR POTENTIATE THE PRESSOR EFFECTS OF THE DRUG
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
INCREASED RISK OF VASCULAR OCCLUSION
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|